Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	3/28/2005 11:18:39 AM
	Read Replies (1) of 3044

Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for Injection in Second-Line Multiple Myeloma CAMBRIDGE, Mass., March 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the Company will be focusing on the recent full approval of VELCADE in relapsed refractory multiple myeloma (MM) at the upcoming Citigroup Smith Barney Healthcare Conference. Management will discuss the significant survival advantage that was demonstrated in a phase III study comparing VELCADE to a standard therapy, the results of which led to the expanded label in the treatment of patients with MM who have received at least one prior therapy. [snip] presentation at the Citigroup Smith Barney Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website: 3:55 p.m. EST Tuesday, March 29, 2005 millennium.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next